Department of Biochemistry and Molecular Biology, SUNY Upstate Medical University, Syracuse, NY 13210, USA.
Department of Biochemistry and Molecular Biology, SUNY Upstate Medical University, Syracuse, NY 13210, USA; School of Graduate Studies, Rutgers Biomedical and Health Sciences, Rutgers University, Piscataway, NJ 08854, USA.
Biochim Biophys Acta Gene Regul Mech. 2019 Sep;1862(9):194408. doi: 10.1016/j.bbagrm.2019.194408. Epub 2019 Aug 2.
In Saccharomyces cerevisiae, Core Factor (CF) is a key evolutionarily conserved transcription initiation factor that helps recruit RNA polymerase I (Pol I) to the ribosomal DNA (rDNA) promoter. Upregulated Pol I transcription has been linked to many cancers, and targeting Pol I is an attractive and emerging anti-cancer strategy. Using yeast as a model system, we characterized how CF binds to the Pol I promoter by electrophoretic mobility shift assays (EMSA). Synthetic DNA competitors along with anti-tumor drugs and nucleic acid stains that act as DNA groove blockers were used to discover the binding preference of yeast CF. Our results show that CF employs a unique binding mechanism where it prefers the GC-rich minor groove within the rDNA promoter. In addition, we show that yeast CF is able to bind to the human rDNA promoter sequence that is divergent in DNA sequence and demonstrate CF sensitivity to the human specific Pol I inhibitor, CX-5461. Finally, we show that the human Core Promoter Element (CPE) can functionally replace the yeast Core Element (CE) in vivo when aligned by conserved DNA structural features rather than DNA sequence. Together, these findings suggest that the yeast CF and the human ortholog Selectivity Factor 1 (SL1) use an evolutionarily conserved, structure-based mechanism to target DNA. Their shared mechanism may offer a new avenue in using yeast to explore current and future Pol I anti-cancer compounds.
在酿酒酵母中,核心因子(CF)是一种关键的进化保守转录起始因子,有助于将 RNA 聚合酶 I(Pol I)募集到核糖体 DNA(rDNA)启动子。上调的 Pol I 转录与许多癌症有关,针对 Pol I 是一种有吸引力的新兴抗癌策略。我们使用酵母作为模型系统,通过电泳迁移率变动分析(EMSA)来表征 CF 如何与 Pol I 启动子结合。使用合成 DNA 竞争物以及作为 DNA 沟阻滞剂的抗肿瘤药物和核酸染色剂来发现酵母 CF 的结合偏好。我们的结果表明,CF 采用了一种独特的结合机制,它更喜欢 rDNA 启动子中富含 GC 的小沟。此外,我们表明酵母 CF 能够结合人 rDNA 启动子序列,该序列在 DNA 序列上存在差异,并证明 CF 对人特异性 Pol I 抑制剂 CX-5461 敏感。最后,我们表明,当通过保守的 DNA 结构特征而不是 DNA 序列对齐时,人核心启动子元件(CPE)可以在体内替代酵母核心元件(CE)发挥功能。总之,这些发现表明,酵母 CF 和人类同源物选择因子 1(SL1)使用一种进化保守的、基于结构的机制来靶向 DNA。它们的共享机制可能为使用酵母探索当前和未来的 Pol I 抗癌化合物提供了一条新途径。